Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort.


Journal

BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061

Informations de publication

Date de publication:
05 2021
Historique:
received: 02 09 2020
revised: 28 10 2020
accepted: 16 04 2021
entrez: 6 5 2021
pubmed: 7 5 2021
medline: 18 5 2021
Statut: ppublish

Résumé

Following the recent COVID-19 lockdown, a reduction in emergency healthcare visits was reported. Infectious diseases were less often diagnosed, while it was not clear if this was due to a decrease in prevalence or a decrease in emergency healthcare visits due to fear of COVID-19. This study comprises a follow-up from a recently finished randomised controlled trial, to gain insight into the prevalence of asthma exacerbation and fear of COVID-19 in patients with moderate-severe asthma and controls in the Netherlands. Participants, patients with asthma and controls, were invited to fill out a short survey by email or post. Exacerbation frequencies until 1 July 2020 were verified with the hospitals' and general practitioners' medical records, pharmacies and patient interviews. In quarter 2 of 2020, mean exacerbation frequency per patient was significantly lower (χ In conclusion, we found a significantly reduced asthma exacerbation frequency during COVID-19 social distancing measures compared with previous years. Patients with asthma also showed more anxiety towards (acquiring) COVID-19 infection. NL8576.

Identifiants

pubmed: 33952584
pii: 8/1/e000758
doi: 10.1136/bmjresp-2020-000758
pmc: PMC8102860
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Clin Rev Allergy Immunol. 2020 Aug;59(1):78-88
pubmed: 32468411
Allergy. 2021 Mar;76(3):866-868
pubmed: 32479648
Clin Infect Dis. 2013 Feb;56(4):509-16
pubmed: 23087391
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Allergy. 2020 Oct;75(10):2503-2541
pubmed: 32535955
Can J Neurol Sci. 2020 Sep;47(5):693-696
pubmed: 32450927
J Korean Med Sci. 2020 May 18;35(19):e182
pubmed: 32419400
J Clin Epidemiol. 1994 Jan;47(1):81-7
pubmed: 8283197
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3
pubmed: 32333915
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Psychol Med. 1997 Mar;27(2):363-70
pubmed: 9089829

Auteurs

Geertje de Boer (G)

Pulmonary Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands g.m.deboer@erasmusmc.nl.
Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.

Gert-Jan Braunstahl (GJ)

Pulmonary Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.
Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.

Rudi Hendriks (R)

Pulmonary Medicine, Erasmus MC, Rotterdam, The Netherlands.

Gerdien Tramper-Stranders (G)

Pediatrics, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH